Enanta Pharmaceuticals (ENTA) Return on Sales (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2025 and bottomed at 0.02% in Q1 2023.
• The 5-year median for Return on Sales is 0.01% (2023), against an average of 0.01%.
• Peak annual rise in Return on Sales reached 2 bps in 2022, while the deepest fall reached 1 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 0.01% in 2022, then sank by 51 bps to 0.02% in 2023, then climbed by 29 bps to 0.01% in 2024, then surged by 51 bps to 0.01% in 2025, then retreated by 19 bps to 0.01% in 2026.
• The last three Return on Sales figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

Peer Comparison